The Pharmacy Times® Neurology Resource Center is a comprehensive resource for clinical news and expert insights on disorders of the nervous system, including multiple sclerosis, Alzheimer disease, migraine, and Parkinson disease.
May 9th 2024
The results also showed that the PET scans could show damage to the individual’s brains, which was correlated with disability and fatigue.
Understanding the Role of IVIg and SCIg for the Management of CIDP: Information the Pharmacist Needs to Know to Optimize Care, featuring a Patient Perspective
1.5 Credits / Immunology, Neurology
View More
Rare and Treatment-Resistant Epilepsy Syndromes: Identifying and Addressing the Unmet Needs of Patients and Recognizing Opportunities for Pharmacist Intervention
1.5 Credits / Neurology
View More
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Navigating the Use of Targeted Therapies and Individualizing Care for Patients With Ulcerative Colitis
1.5 Credits / Gastroenterology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Advances in Pharmacotherapy for Excessive Daytime Sleepiness Due to Narcolepsy
2.0 Credits / Neurology
View More
The Role of Long-Term Care and Consultant Pharmacists in the Management of Tardive Dyskinesia
1.0 Credit / Neurology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Genzyme Seeks Approval for Multiple Sclerosis Drug Lemtrada
June 20th 2012Sanofi's Genzyme unit announced in a press release earlier last week that the company has submitted an application to regulatory authorities for approval of Lemtrada (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS).
Read More
Regulatory Authorities Accept Oral BG-12 Marketing Applications For Review
May 11th 2012Biogen Idec recently announced that United States and European Union regulatory authorities have accepted the company's marketing applications for the review of BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of multiple sclerosis (MS).
Read More
FDA Issues Alert on Unproven Treatment for Multiple Sclerosis
May 10th 2012The Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called "liberation therapy" or the "liberation procedure" to treat chronic cerebrospinal venous insufficiency (CCSVI).
Read More
Biogen Idec Submits Application to FDA for Approval of Oral BG-12 to Treat Multiple Sclerosis
March 1st 2012Yesterday Biogen Idec announced the company has submitted a New Drug Application (NDA) to the FDA for marketing approval of BG-12 (dimethyl fumarate), the company's oral therapeutic candidate for the treatment of multiple sclerosis (MS).
Read More